Related content

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

By        

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 2066-2072

Spandidos Publications

Access to resources Recommend Favorite

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

By Califano Raffaele  

Targeted Oncology, Vol. 3, Iss. 3, 2008-07 ,pp. : 173-186

Springer Publishing Company

Access to resources Recommend Favorite

Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer

By Shimizu Katsuhiko   Yukawa Takuro   Hirami Yuji   Okita Riki   Saisho Shinsuke   Maeda Ai   Yasuda Koichiro   Nakata Masao  

Targeted Oncology, Vol. 8, Iss. 4, 2013-12 ,pp. : 237-242

Springer Publishing Company

Access to resources Recommend Favorite

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 391-396

Spandidos Publications

Access to resources Recommend Favorite